Recently, the 24th Shanghai International Biotechnology and Pharmaceutical Symposium (BIO-FORUM) series｜China Biotechnology and Pharmaceutical Innovation Forum and 2022 China Biomedical Science and Technology Innovation Value List Award was held in Shanghai. As a leading orthopedic surgical robotics company, TZH was successfully selected as one of the TOP 20 most influential innovative medical device companies.
The selection was guided by Shanghai Biomedical Science and Technology Development Center (SBSTDC), Science and Technology Commission of Jing'an District of Shanghai, and Shanghai Daning Asset Management (Group) Company Limited, and initiated by the Shanghai Biomedical Association (SBMA) together with MediWorks Technology (MWT). There are 9 series of selection projects, including small molecule innovative drugs, antibody drugs, innovative therapeutics, biotechnology, medical devices, CXOs, biomedical industrial parks, brokerage firms, investment banks, and financial service institutions, and the evaluation team will standardize and comprehensively evaluate the annual data and public information of biomedical enterprises in 2021, so as to select a group of enterprises with innovative value in the industry in the current year.
The innovative medical device list focuses on imaging devices, cardiovascular and cerebrovascular implant/intervention, and surgical robots, and TZH has been widely recognized in the industry for its in-depth cultivation and innovation in orthopedic surgical robots and related technologies.
Since its inception, TZH has been focusing on independent innovation, large-scale production, specialized marketing and high-quality clinical applications of orthopedic surgical robots and their related technologies, and is the first company in China and the world's fifth company to obtain the registration license for medical robots, and at the same time, the company is a member of the China Robotics TOP10, and the medical robotics national and local joint engineering research centers dependency. .
According to the three-quarterly report announced earlier, in the first three quarters of 2022, Tianzhihang R & D investment totaled 80,328,800 yuan, an increase of 14.95% over the same period of the previous year, at the same time this part of the funds accounted for the proportion of revenue reached 95.33%, accounting for 28.65 percentage points compared to the same period of the previous year is still increased.
With continuous investment in research and development, Tianzhihang has established a stable and efficient production, learning, research and medical innovation mechanism by relying on the Beijing Engineering Laboratory of Medical Robotics, the State Joint Engineering Research Center of Medical Robotics, the Medical Robotics Industry Innovation Center, and Tsinghua University, Beijing University of Aeronautics and Astronautics, and Beijing Jishuitan Hospital, the People's Liberation Army General Hospital and other advantageous health care institutions. The company has established a stable and efficient mechanism of collaborative innovation among industry, academia, research and medicine. In addition, the company has undertaken a number of national and local scientific research tasks and achieved a series of research results.
Tianzhihang's core product, Tiangui Orthopedic Surgical Robot, can be used to assist doctors to precisely locate implants or surgical instruments, and can be widely used in spine and trauma orthopedic surgeries, with a clinical accuracy of up to 1mm or less. In practice, as of the end of the third quarter of 2022, the cumulative number of surgeries carried out by TKA orthopedic surgical robots has exceeded 30,000 cases, and has been applied in more than 150 hospitals in China, which is a leading position in the country. In addition, the company's TKA total knee replacement robot clinical trial enrollment work, namely, clinical trial surgery has been fully completed, is expected to be licensed and listed in the first half of 2023.
If you want to know more financial news in real time, welcome to follow us.